Brands
India, Uzbekistan launch pharma and nutraceutical trade corridor
New partnership positions Uzbekistan as gateway to a USD 10 bn Eurasian health market
TASHKENT: India’s pharmaceutical and nutraceutical industries are getting a new route into Eurasia, and it runs through Tashkent.
The ministry of health of the republic of Uzbekistan has partnered with nutrify today and pharma eurasia to launch a structured indo–cis pharmaceutical and nutraceutical trade corridor. The initiative aims to streamline market access for Indian and global companies into the commonwealth of independent states and the wider Eurasian region.
The corridor brings together government policy support, industry leadership and a commercial platform designed to translate high-level discussions into actual trade deals. Pharma Eurasia 2026, scheduled in Tashkent from 20 to 22 May, will serve as the main marketplace where these opportunities are expected to materialise.
The timing is significant. The dietary supplements market across the CIS is already worth more than $ 5.8 billion annually, while the wider Eurasian nutraceutical sector is estimated at $ 7 billion to $ 10 billion and expanding quickly. Demand is being driven by rising interest in preventive healthcare, the spread of organised pharmacy chains and growing consumer appetite for vitamins, botanicals and functional nutrition products.
For Indian exporters, the corridor offers a structured entry point into these markets. The initiative also comes as regulatory systems across several CIS economies are tightening, creating greater demand for quality-certified products.
Uzbekistan is positioning itself as the region’s health industry gateway. In recent years the country has invested heavily in pharmaceutical parks, industrial clusters and regulatory reforms designed to attract foreign investment and manufacturing partnerships. Tashkent’s pharma park is intended to provide overseas pharmaceutical and nutraceutical firms with a clear pathway to establish production or distribution bases with government support.
The new trade corridor operates on what organisers call a dual-city model. Strategic dialogue and industry leadership discussions will take place in Mumbai through the sumflex and c-suite summit platforms, bringing together global CEOs, regulators and investors. The commercial follow-through will happen in Tashkent at pharma eurasia, where partnerships, regulatory engagement and buyer connections are expected to move deals forward.
Pharma Eurasia 2026 is designed as a meeting ground for manufacturers, ingredient suppliers, contract development and manufacturing organisations, distributors and regulatory experts from across the region. Under the new partnership, the exhibition will also function as the annual marketplace for the Indo–CIS health trade corridor.
Beyond trade deals, the corridor’s agenda includes regulatory harmonisation, digitalisation of supply chains, investment facilitation and joint research opportunities. Nutrify today plans to deploy AI-driven regulatory intelligence tools to support compliance and cross-border nutraceutical trade.
The ministry of health of the Republic of Uzbekistan first deputy minister of health and chairman of pharmaceutical industry development agency Abdulla Azizov said Ubekistan is well positioned to act as a strategic bridge between India and the CIS region while building a transparent, technology-enabled trade ecosystem.
Nutrify today MTI executive director Khasim said the initiative connects global leadership dialogue in Mumbai with a structured commercial platform in Tashkent, helping translate strategic discussions into executable trade architecture.
Tricornio technologies vice president and pharma eurasia project director m. harikrishnan said the platform aims to create a long-term, policy-aligned ecosystem where innovation, compliance and cross-border healthcare trade can grow in a sustainable and scalable manner.
The ministry of health of the Republic of Uzbekistan chief international relations specialist Kamila Mirzaeva said the collaboration introduces digital tools and transparent frameworks into a more institutionalised trade architecture, while also encouraging joint ventures in manufacturing, technology transfer and regional expansion.
With demand for preventive health products rising globally, the new corridor could offer Indian manufacturers a fresh gateway into a fast-growing Eurasian market while reinforcing Uzbekistan’s ambition to become a regional pharmaceutical hub.
Brands
Godrej clarifies ‘GI’ identifier after logo similarity debate
Says GI is not a logo, will not replace Godrej signature across products.
MUMBAI: In a branding storm where shapes did the talking, Godrej is now spelling things out. Godrej Industries Group (GIG) has issued a clarification on its newly introduced ‘GI’ identifier, addressing questions around its purpose and design following a wave of online criticism. At the centre of the debate were two concerns: whether the new mark replaces the long-standing Godrej logo, and whether its geometric design mirrors other corporate identities.
The company has drawn a clear line. The Godrej signature logo, it said, remains unchanged and continues to be the sole logo across all consumer-facing products and services. The ‘GI’ mark, by contrast, is not a logo but a corporate group identifier intended for use alongside the Godrej signature or company name, and aimed at stakeholders such as investors, media and talent rather than consumers.
The need for such a distinction stems from the 2024 restructuring of the broader Godrej Group into two separate business entities. With both continuing to operate under the same Godrej name and signature, the identifier is positioned as a way to differentiate the Godrej Industries Group at a corporate level.
The rollout, however, triggered a broader conversation on design originality. Critics pointed to similarities between the GI mark’s geometric composition and logos used by companies globally, raising questions about distinctiveness.
Responding to this, GIG said its intellectual property and legal review found that such overlaps are common in minimalist, geometry-led design systems. Basic forms such as circles and rectangles appear across dozens of brand identities worldwide, the company noted.
It added that the identifier emerged from an extensive design process and was chosen for its simplicity, allowing it to sit alongside the Godrej signature without competing visually. While acknowledging that elemental shapes may appear less distinctive in isolation, the group emphasised that the mark is part of a broader identity system that includes a custom typeface, sonic branding and other proprietary elements.
Following legal and ethical assessments, the company said it found no impediment to using the identifier, reiterating that the GI mark is a corporate tool not a consumer-facing symbol.
In short, the logo isn’t changing but the conversation around it certainly has.
